

Anti-angiogenic therapies in cancer clinical trials

Expert Opinion on Investigational Drugs

7, 1629-1655

DOI: [10.1517/13543784.7.10.1629](https://doi.org/10.1517/13543784.7.10.1629)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chapter 15. Matrix metalloproteinase inhibitors for treatment of cancer. Annual Reports in Medicinal Chemistry, 2000, 35, 167-176.	0.5	20
2	Current Status Of Antiangiogenic Factors. British Journal of Haematology, 2000, 109, 477-489.	1.2	78
3	VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH SUPERFICIAL BLADDER CANCER RECURRENCE RATES AND STAGE PROGRESSION. Urologic Clinics of North America, 2000, 27, 191-197.	0.8	25
5	Tumor angiogenesis as a therapeutic target. Drug Discovery Today, 2001, 6, 1005-1024.	3.2	108
6	Angiogenic Growth Factors: Autocrine and Paracrine Regulation of Survival in Hematologic Malignancies. Oncologist, 2001, 6, 4-7.	1.9	31
7	Concise stereocontrolled routes to fumagillol, fumagillin, and TNP-470. Chirality, 2003, 15, 156-166.	1.3	25
8	Investigation of novel fumagillin analogues as angiogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 91-94.	1.0	24
9	Angiogenic and antiangiogenic gene therapy. Gene Therapy, 2005, 12, S159-S169.	2.3	29
10	Design, Synthesis, and Antiangiogenic Effects of a Series of Potent Novel Fumagillin Analogues. Chemical and Pharmaceutical Bulletin, 2007, 55, 1024-1029.	0.6	10
11	Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis. BJU International, 2007, 86, 80-86.	1.3	37
12	In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. British Journal of Cancer, 2007, 96, 1368-1376.	2.9	39
13	The Characteristics of Vascular Growth in VX2 Tumor Measured by MRI and Micro-CT. Journal of Oncology, 2012, 2012, 1-7.	0.6	7
14	Construction of a bicistronic proangiogenic expression vector and its application in experimental angiogenesis in vivo.. Acta Biochimica Polonica, 2003, 50, 875-882.	0.3	7